论文部分内容阅读
目的系统分析奥马珠单抗治疗难治型变应性鼻炎的疗效及安全性。方法通过搜索PubMed,Cochrane Library,CNKI及万方数据库,收集奥马珠单抗治疗难治型变应性鼻炎的随机对照试验(RCT),使用Revman 5.3软件对数据进行Meta分析,评价奥马珠单抗的疗效及安全性。结果 Meta分析结果显示,奥马珠单抗在降低鼻部症状方面差异有统计学意义,药物引起的不良反应差异无统计学意义。结论奥马珠单抗在缓解鼻部症状等方面具有显著的效果,是一种相对安全的药物。
Objective To analyze the efficacy and safety of omalizumab in the treatment of refractory allergic rhinitis. Methods A randomized controlled trial (RCT) of omeizumab in the treatment of refractory allergic rhinitis was conducted by searching PubMed, Cochrane Library, CNKI and Wanfang database. Meta-analysis was performed using Revman 5.3 software to evaluate the effect of omalizumab The efficacy and safety. Results Meta analysis showed that omalizumab in reducing nasal symptoms was statistically significant, drug-induced adverse reactions was not statistically significant. Conclusion Omalizumab has a significant effect in relieving nasal symptoms and is a relatively safe drug.